B W Robinson

Summary

Affiliation: University of Western Australia
Country: Australia

Publications

  1. ncbi request reprint Climbing Mount Kilimanjaro in a blizzard
    Bruce W S Robinson
    School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, WA
    Med J Aust 181:646-8. 2004
  2. ncbi request reprint A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent
    Cleo Robinson
    School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Perth, Australia
    Cancer Res 66:10786-94. 2006
  3. ncbi request reprint Advances in malignant mesothelioma
    Bruce W S Robinson
    School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, Perth, Australia
    N Engl J Med 353:1591-603. 2005
  4. ncbi request reprint Localised spontaneous regression in mesothelioma -- possible immunological mechanism
    B W Robinson
    University Department of Medicine, University of Western Australia, Sir Charles Gairdner Hospital, G Block, 4th Floor, Monash Avenue, 6009, Nedlands, Australia
    Lung Cancer 32:197-201. 2001
  5. ncbi request reprint Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance
    B W Robinson
    University Department of Medicine, University of Western Australia, Nedlands, Australia
    Clin Cancer Res 7:811s-817s. 2001
  6. ncbi request reprint Malignant mesothelioma
    Bruce W S Robinson
    Tumour Immunology Group, School of Medicine and Pharmacology, University of Western Australia, Australia
    Lancet 366:397-408. 2005
  7. ncbi request reprint Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation
    B W Robinson
    University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia
    Immunol Cell Biol 77:552-8. 1999
  8. ncbi request reprint Mesothelin-family proteins and diagnosis of mesothelioma
    Bruce W S Robinson
    University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Western Australia, Perth, Australia
    Lancet 362:1612-6. 2003
  9. ncbi request reprint Soluble mesothelin-related protein--a blood test for mesothelioma
    Bruce W S Robinson
    University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Perth, WA, Australia
    Lung Cancer 49:S109-11. 2005
  10. ncbi request reprint IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2
    Connie Jackaman
    School of Medicine and Pharmacology, University of Western Australia
    J Immunol 171:5051-63. 2003

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Climbing Mount Kilimanjaro in a blizzard
    Bruce W S Robinson
    School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, WA
    Med J Aust 181:646-8. 2004
  2. ncbi request reprint A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent
    Cleo Robinson
    School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Perth, Australia
    Cancer Res 66:10786-94. 2006
    ..These data provide the first in vivo demonstration of co-carcinogenicity between SV40 and asbestos...
  3. ncbi request reprint Advances in malignant mesothelioma
    Bruce W S Robinson
    School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, Perth, Australia
    N Engl J Med 353:1591-603. 2005
  4. ncbi request reprint Localised spontaneous regression in mesothelioma -- possible immunological mechanism
    B W Robinson
    University Department of Medicine, University of Western Australia, Sir Charles Gairdner Hospital, G Block, 4th Floor, Monash Avenue, 6009, Nedlands, Australia
    Lung Cancer 32:197-201. 2001
    ..The patient survived for 20 months and, in contrast to her initial biopsy, no significant lymphoid infiltrate was detected in her MM tissue at post mortem examination...
  5. ncbi request reprint Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance
    B W Robinson
    University Department of Medicine, University of Western Australia, Nedlands, Australia
    Clin Cancer Res 7:811s-817s. 2001
    ..These data suggest that ignorance is not an explanation for the failure of the host immune system to respond to tumor antigens...
  6. ncbi request reprint Malignant mesothelioma
    Bruce W S Robinson
    Tumour Immunology Group, School of Medicine and Pharmacology, University of Western Australia, Australia
    Lancet 366:397-408. 2005
    ..Gene therapy and immunotherapy are used on an experimental basis only. Patterns identified from microarray studies could be useful for diagnosis as well as prognostication...
  7. ncbi request reprint Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation
    B W Robinson
    University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia
    Immunol Cell Biol 77:552-8. 1999
    ..We have also used this technology to evaluate the effects of antitumour therapy on local antigen cross-presentation...
  8. ncbi request reprint Mesothelin-family proteins and diagnosis of mesothelioma
    Bruce W S Robinson
    University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Western Australia, Perth, Australia
    Lancet 362:1612-6. 2003
    ..Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals...
  9. ncbi request reprint Soluble mesothelin-related protein--a blood test for mesothelioma
    Bruce W S Robinson
    University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Perth, WA, Australia
    Lung Cancer 49:S109-11. 2005
    ..SMRP should also be useful for monitoring disease progression, and importantly, may prove useful for screening asbestos-exposed individuals for early MM...
  10. ncbi request reprint IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2
    Connie Jackaman
    School of Medicine and Pharmacology, University of Western Australia
    J Immunol 171:5051-63. 2003
    ..t. (but not systemic) IL-2 mediates tumor regression via an enhanced endogenous tumor-specific CTL response concomitant with reduced vasculature, thereby demonstrating a novel mechanism for IL-2 activity...
  11. ncbi request reprint Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma
    C C Leong
    Australian Neuromuscular Research Institute, Queen Elizabeth II Medical Centre, Nedlands
    Int J Cancer 71:476-82. 1997
    ..Our observations are relevant to human MM because these cell lines have been derived from asbestos-induced tumors and share many properties with human cell lines of the same histological type...
  12. ncbi request reprint The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor
    S Mukherjee
    Department of Medicine, University of Western Australia, Perth, Australia
    Cancer Gene Ther 8:580-8. 2001
    ..This has implications for the future design of human gene therapy trials for solid tumors such as MM...
  13. doi request reprint Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy
    Steve A Broomfield
    School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    J Immunol 182:5217-24. 2009
    ..These results demonstrate that antitumor responses induced by locally delivered TLR7 agonists can be harnessed systemically for treating distal tumor...
  14. doi request reprint Deliberately provoking local inflammation drives tumors to become their own protective vaccine site
    Connie Jackaman
    School of Biomedical Sciences, Curtin University, Kent St Bentley, Perth, Western Australia 6102, Australia
    Int Immunol 20:1467-79. 2008
    ..We conclude that provoking intra-tumoral inflammation skews the tumor microenvironment from tumorigenic to immunogenic, resulting in the resolution of treated and untreated distal tumors, as well long-term protective memory...
  15. ncbi request reprint Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells
    Anna K Nowak
    Tumor Immunology Group, Department of Medicine, University of Western Australia and Western Australian Institute of Medical Research, Perth, Australia
    J Immunol 170:4905-13. 2003
    ..This observation has fundamental consequences for the development of tumor immunotherapy protocols and for understanding T cell reactivity to tumors and the in vivo immune responses to apoptotic cells...
  16. doi request reprint Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation
    Andrew J Currie
    National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    J Immunol 183:7898-908. 2009
    ..Thus, PD-L1 blockade activates antitumor CD8 T cell most potently in the absence of CD4 T cells. These findings have implications for the development of PD-L1-based therapies...
  17. pmc p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
    J Creaney
    Western Australian Institute for Medical Research and University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, 4th Floor, G Block, Nedlands, Perth, 6009, Western Australia
    Br J Cancer 84:52-6. 2001
    ..The occurrence of anti-p53 antibodies does not serve as either a useful prognostic or diagnostic indicator in MM...
  18. ncbi request reprint Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo
    A L Marzo
    The University of Western Australia Department of Medicine, Queen Elizabeth II Medical Centre, Nedlands, Perth
    Cancer Res 57:3200-7. 1997
    ..These data show that the blockade of TGF-beta2 within this tumor reduces tumor growth and raises the possibility that TGF-beta2 antisense ODNs may be useful as a therapy for this disease...
  19. pmc Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth
    Robbert G van der Most
    National Research Centre for Asbestos Related Diseases, University of Western Australia, Perth, Australia
    PLoS ONE 4:e6982. 2009
    ..Pre-clinical models clearly demonstrate that chemotherapy can synergize with immunotherapy, raising the question how the immune system can be mobilized to generate anti-tumor immune responses in the context of chemotherapy...
  20. ncbi request reprint Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors
    Anna K Nowak
    University Department of Medicine, Western Australian Institute for Medical Research, Queen Elizabeth II Medical Centre, 4th Floor, G Block, Nedlands, Perth, Western Australia 6009
    Cancer Res 63:4490-6. 2003
    ..This study provides evidence that chemotherapy has the capacity to augment cellular antitumor immunity, a finding with wider implications for the management of treatment-resistant solid tumors...
  21. ncbi request reprint New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents
    Anna K Nowak
    University Department of Medicine, University of Western Australia, Verdun St Nedlands, Australia
    Semin Oncol 29:82-96. 2002
    ..The development of more active cytotoxic combinations in this disease should facilitate further studies of chemoimmunotherapy. It seems likely that no single treatment modality will be effective by itself...
  22. ncbi request reprint Soluble mesothelin related protein in mesothelioma
    Jenette Creaney
    School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Wedlands, WA, Australia
    J Thorac Oncol 1:172-4. 2006
  23. ncbi request reprint Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors
    Christine S Bundell
    School of Medicine and Pharmacology, University of Western Australia, 4th Floor, G Block, Queen Elizabeth II Medical Centre, Perth, WA 6009, Australia
    Cancer Immunol Immunother 55:933-47. 2006
    ..However, intra-tumoral IL-2 treatment altered the potency, but not the hierarchy, of these CTL such that they mediated tumor regression. These results have implications for immunotherapy protocols...
  24. ncbi request reprint Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity
    Robbert G van der Most
    School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Perth 6009, Australia
    Cancer Res 66:601-4. 2006
    ..We argue that this process could affect the way that a tumor works as its own cellular vaccine, and that it is differentially modulated by the choice of treatment...
  25. pmc Asbestos fibres inhibit the in vitro activity of lymphokine-activated killer (LAK) cells from healthy individuals and patients with malignant mesothelioma
    L S Manning
    University Department of Medicine, Queen Elizabeth II Medical Centre, Nedlands, Western Australia
    Clin Exp Immunol 83:85-91. 1991
    ..01). These findings suggest that asbestos exposure may suppress the function and in some instances the generation of immune effector cell mechanisms, thereby increasing the risk of disease and malignancy...
  26. ncbi request reprint Immunotherapy and chemotherapy--a practical partnership
    Richard A Lake
    Tumour Immunology Group, School of Medicine and Pharmacology, Western Australian Institute for Medical Research, Perth, 6009, Australia
    Nat Rev Cancer 5:397-405. 2005
    ..These data have significant implications for the development of new protocols combining chemotherapy with immunotherapy, indicating an exciting potential for therapeutic synergy with general applicability to many cancer types...
  27. ncbi request reprint Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma
    Jenette Creaney
    National Research Centre for Asbestos Related Diseases, 4th Floor, G Block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia
    Chest 132:1239-46. 2007
    ..The purpose of this study was to study the mesothelin biomarker in a large patient cohort and to determine if another biomarker, CA125, improves on the sensitivity of mesothelin in the diagnosis of mesothelioma...
  28. ncbi request reprint Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors
    Andrew J Currie
    National Research Centre for Asbestos Related Diseases, QEII Medical Centre, Verdun Street, Nedlands, Perth 6009, Western Australia
    J Immunol 180:1535-44. 2008
    ..These studies suggest that, once reactivated, pre-existing local CD8 T cell responses are sufficient to resolve established tumors and that in situ type I IFN is a determining factor...
  29. doi request reprint Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma
    Jenette Creaney
    National Research Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia
    J Thorac Oncol 3:851-7. 2008
    ....
  30. doi request reprint Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
    Robbert G van der Most
    National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    Cancer Immunol Immunother 58:1219-28. 2009
    ..Cyclophosphamide could be used to achieve regulatory T cell depletion in combination with chemotherapy...
  31. ncbi request reprint Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation
    Philip A Stumbles
    School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia
    J Immunol 173:5923-8. 2004
    ..These data indicate that CD40 activation enhances the peripheral survival of constitutively cross-armed CTL and that persistent CD4+ T cell signals are required for their long-term activity...
  32. doi request reprint Serum and pleural fluid biomarkers for mesothelioma
    Jenette Creaney
    National Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, University of Western Australia, 4th Floor, G Block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia
    Curr Opin Pulm Med 15:366-70. 2009
    ..With the incidence of malignant mesothelioma expected to increase, it is timely to review the current status of biomarkers in this field...
  33. doi request reprint CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor
    Alison M McDonnell
    School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia
    Eur J Immunol 40:1617-27. 2010
    ..Migratory tumor DC subsets with altered co-stimulatory receptor expression may contribute to induction and regulation of tumor-specific responses...
  34. doi request reprint Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma
    Jenette Creaney
    National Research Centre for Asbestos Related Disease, Sir Charles Gairdner Hospital, 2School of Medicine and Pharmacology, University of Western Australia, QEII Medical Centre, Nedlands, Western Australia, Australia
    Cancer Epidemiol Biomarkers Prev 19:2238-46. 2010
    ..In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma...
  35. pmc Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
    Jenette Creaney
    Department of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Verdun Ave, Nedlands 6009, Western Australia, Australia
    Thorax 62:569-76. 2007
    ....
  36. ncbi request reprint Combined chemoimmunotherapy of solid tumours: improving vaccines?
    Anna K Nowak
    Department of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, 4th Floor, G Block, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009 Australia
    Adv Drug Deliv Rev 58:975-90. 2006
    ....
  37. ncbi request reprint Sensitivity of urinary mesothelin in patients with malignant mesothelioma
    Jenette Creaney
    National Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
    J Thorac Oncol 5:1461-6. 2010
    ....
  38. ncbi request reprint Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein
    Jenette Creaney
    School of Medicine and Pharmacology, University of Western Australia, 4th Floor, G Block, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia
    Hematol Oncol Clin North Am 19:1025-40, v. 2005
    ....
  39. ncbi request reprint Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy
    H Bielefeldt-Ohmann
    University of Western Australia Department of Medicine, Queen Elizabeth II Medical Centre, Nedlands
    Cancer Immunol Immunother 40:241-50. 1995
    ....
  40. pmc Private specificities can dominate the humoral response to self-antigens in patients with cryptogenic fibrosing alveolitis
    C Robinson
    University Department of Medicine, Western Australian Institute for Medical Research, Queen Elizabeth II Medical Centre, Perth, Australia
    Respir Res 2:119-24. 2001
    ..This suggests that the antibodies are epiphenomenal and are a secondary feature of tissue damage induced by some other mechanism...
  41. ncbi request reprint Expression and integrity of DNA topoisomerase II isoforms does not explain generic drug resistance in malignant mesothelioma
    B R McLaren
    Western Australian Institute for Medical Research, University Department of Medicine, University of Western Australia, Perth, Australia
    Cancer Chemother Pharmacol 48:1-8. 2001
    ..CONCLUSION: We conclude that mutations in topoisomerase IIalpha can be associated with extreme resistance of mesothelioma to etoposide. The generic drug resistance of this tumour requires further investigation...
  42. ncbi request reprint Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12
    Sutapa Mukherjee
    Department of Medicine, University of Western Australia, Perth, Australia
    Cancer Gene Ther 10:591-602. 2003
    ....
  43. ncbi request reprint Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy
    Steve Broomfield
    School of Medicine and Pharmacology and Western Australian Institute for Medical Research, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Perth, Australia
    Cancer Res 65:7580-4. 2005
    ..We postulate that chemotherapy induced apoptosis of the residual tumor cells following incomplete resection is absolutely required for the induction of long-term immunologic memory...
  44. ncbi request reprint Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy
    Anna K Nowak
    Western Australian Institute for Medical Research, University Department of Medicine, Queen Elizabeth II Medical Centre, 4th Floor, G Block, Nedlands, Perth, Western Australia 6009
    Cancer Res 62:2353-8. 2002
    ..In contrast, vaccination protocols requiring a humoral immune response for maximal efficacy may be compromised in patients treated with gemcitabine...
  45. ncbi request reprint MHC multimerization, antigen expression and the induction of APC amnesia in the developing immune response
    R A Lake
    University Department of Medicine, Queen Elizabeth II Medical School, Nedlands, Perth, Australia
    Immunol Cell Biol 77:99-104. 1999
    ..In the present article, we propose that multimerization can result in the specific removal of ligand complexes from the cell surface of the APC, an event which may influence the overall pattern of T cell reactivity...
  46. ncbi request reprint Intratumoral poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model
    Ivonne van Bruggen
    University of Western Australia, School of Medicine and Pharmacology, Perth, Western Australia 6009
    J Immunother 28:359-67. 2005
    ..Hence, the IL-2/gel may provide a microenvironment that allows intratumoral T cells to proliferate and retain their cytolytic functions as they encounter their cognate antigens expressed by tumor cells...
  47. ncbi request reprint Current chemotherapeutic treatment of malignant pleural mesothelioma
    Anna K Nowak
    University of Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
    Expert Opin Pharmacother 5:2441-9. 2004
    ..This combination has become the standard of care in mesothelioma treatment...
  48. ncbi request reprint ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells
    Jun Zhong
    Department of Pharmacology, The Woolcock Institute of Medical Research, University of Sydney, New South Wales, Australia
    J Cell Physiol 207:540-52. 2006
    ..Mesothelioma progression depends on an interaction with mesothelial cells that provide MT1-MMP necessary to activate pro-MMP-2 to facilitate migration through an extracellular matrix (ECM) layer...
  49. ncbi request reprint A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions
    Andrew J Holloway
    Ian Potter Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Clin Cancer Res 12:5129-35. 2006
    ..We have therefore designed a gene expression-based test to classify the primary tumor causing a malignant pleural effusion, using cells collected from the effusion itself...
  50. ncbi request reprint Gene therapy of mesothelioma
    Delia J Nelson
    Curtin University, School of Biomedical Sciences, Kent St, Bentley, Western Australia, 6102 Australia
    Expert Opin Biol Ther 5:1039-49. 2005
    ..Herein, the paper discusses past, present and future views on gene therapy in the treatment of MM...